CRISPR pioneer Feng Zhang's upstart biotech seeks $100M-plus IPO for preclinical base editing work
The CRISPR pioneers’ new, gentler-touch company is aiming for a $100 million initial public offering.
Beam Therapeutics, headed by former Editas founders and gene-editing trailblazers David Liu, Feng Zhang, and J Keith Joung, debuted last year, pushing a softer, more flexible version of gene editing, reflective of a larger trend in the biotech industry. The promise was that instead of hacking at base pairs like first-gen CRISPR does, Beam could instead modify them in a far less disruptive way.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.